Cambridge Investment Research Advisors Inc. Acquires 41,600 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Cambridge Investment Research Advisors Inc. boosted its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 97.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 84,263 shares of the company's stock after acquiring an additional 41,600 shares during the period. Cambridge Investment Research Advisors Inc.'s holdings in Teva Pharmaceutical Industries were worth $1,295,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of TEVA. Bank of New York Mellon Corp lifted its position in Teva Pharmaceutical Industries by 4.3% during the 4th quarter. Bank of New York Mellon Corp now owns 1,621,344 shares of the company's stock valued at $35,734,000 after acquiring an additional 67,571 shares during the period. Metis Global Partners LLC raised its holdings in Teva Pharmaceutical Industries by 6.7% in the fourth quarter. Metis Global Partners LLC now owns 13,697 shares of the company's stock worth $302,000 after buying an additional 860 shares during the last quarter. Jones Financial Companies Lllp raised its holdings in Teva Pharmaceutical Industries by 145.4% in the fourth quarter. Jones Financial Companies Lllp now owns 8,592 shares of the company's stock worth $189,000 after buying an additional 5,091 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Teva Pharmaceutical Industries by 14.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,028,924 shares of the company's stock worth $22,677,000 after buying an additional 129,749 shares during the last quarter. Finally, Victory Capital Management Inc. raised its holdings in Teva Pharmaceutical Industries by 56.8% in the fourth quarter. Victory Capital Management Inc. now owns 3,023,474 shares of the company's stock worth $66,637,000 after buying an additional 1,094,759 shares during the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock remained flat at $17.05 during trading hours on Friday. 5,550,481 shares of the stock were exchanged, compared to its average volume of 10,266,065. The business has a 50 day moving average of $16.99 and a two-hundred day moving average of $17.37. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $22.80. The firm has a market capitalization of $19.56 billion, a price-to-earnings ratio of -14.83, a PEG ratio of 0.87 and a beta of 0.60. The company has a current ratio of 1.03, a quick ratio of 0.74 and a debt-to-equity ratio of 2.59.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 7.74% and a positive return on equity of 45.44%. The firm had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.99 billion. During the same period in the previous year, the business posted $0.48 earnings per share. The business's revenue for the quarter was up 1.9% on a year-over-year basis. Equities research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their target price for the stock from $21.00 to $23.00 in a report on Monday, May 12th. UBS Group decreased their target price on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a report on Thursday, June 26th. Finally, The Goldman Sachs Group assumed coverage on shares of Teva Pharmaceutical Industries in a report on Friday, June 6th. They issued a "buy" rating and a $24.00 target price for the company. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of "Buy" and a consensus price target of $24.13.

Insider Activity at Teva Pharmaceutical Industries

In related news, EVP Matthew Shields sold 6,206 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total transaction of $105,626.12. Following the completion of the sale, the executive vice president directly owned 9,989 shares in the company, valued at approximately $170,012.78. The trade was a 38.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.49% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.